Results 121 to 130 of about 22,080 (229)

Neutrophil‐based immunotherapy: A metabolic lens on mechanisms and therapeutic implications

open access: yesClinical and Translational Medicine, Volume 16, Issue 8, August 2026.
TAN metabolic reprogramming critically contributes to tumour immune evasion. A 4‑Tier TAN‑MetaC classification framework is proposed, along with an overview of translational opportunities and bottlenecks for TAN metabolism‑targeted immunotherapies. Abstract Background Tumor‐associated neutrophils (TANs) serve as pivotal immune modulators in the tumor ...
Wenchao Xu   +4 more
wiley   +1 more source

Generation and Characterization of a Rdh1‐iCre Line to Study Uterine Glandular Biology

open access: yesgenesis, Volume 64, Issue 4, August 2026.
ABSTRACT The uterus is an essential organ for fetal development in most mammals. Uterine glands, highly conserved structures in the mammalian uterus, play critical roles in the establishment and maintenance of pregnancy and have been implicated in the pathogenesis of uterine diseases, including endometrial cancer and endometriosis.
Mana Ohtomo   +11 more
wiley   +1 more source

Urokinase Plasminogen Activator Receptor‐Associated Protein (uPARAP) as a Potential Next Generation Molecular Target for Treatment of Gastrointestinal Stromal Tumors (GIST)

open access: yesInternational Journal of Cancer, Volume 159, Issue 3, Page 797-808, 1 August 2026.
A key component of the collagen internalization and lysosomal degradation cellular machinery, uPARAP may contribute to cancer progression. Here, the authors explored the expression of uPARAP in gastrointestinal stromal tumors using well‐annotated clinical patient samples and specimens from cell line‐ and patient‐derived xenografts.
Chao‐Chi Wang   +10 more
wiley   +1 more source

Lack of Differences in the Pharmacokinetics of Therapeutic Monoclonal Antibodies Between Japanese and Non‐Japanese Individuals

open access: yesThe Journal of Clinical Pharmacology, Volume 66, Issue 8, August 2026.
Abstract Evaluation of the pharmacokinetics (PK) of new drugs in Japanese individuals is regularly requested by the Japanese regulatory agency prior to participation in global clinical trials or for bridging approaches for regulatory approval. However, the need for PK assessments in the Japanese population may be less compelling for monoclonal ...
Paridhi Gupta   +2 more
wiley   +1 more source

Early‐Onset Prostate Cancer: Epidemiology, Risk Factors, Biology, Clinical Features, Management, and Early Detection

open access: yesMedComm, Volume 7, Issue 8, August 2026.
EOPC is a distinct clinicopathological entity separable from SOPC, differing fundamentally in genetic susceptibility, TMPRSS2:ERG fusion frequency, and survival outcomes. Although research remains nascent, this review provides the first comprehensive synthesis of current evidence, offering a critical foundation to guide future investigations into this ...
Xingyu Xiong   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy